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Non-small cell lung cancera b s t r a c t
Immunoglobulin-like transcript (ILT) 4 is critical for the inhibitory function of certain immune cells.
We previously demonstrated that ILT4 is over-expressed in human non-small cell lung cancer
(NSCLC) cells and is involved in tumour evasion via an unknown mechanism. In this report, we
demonstrate that ILT4 increases the expression of the co-inhibitory molecule B7-H3 through
PI3K/AKT/mTOR signalling. In primary human NSCLC tissues, a signiﬁcant positive relationship is
observed between ILT4 and B7-H3 expression. ILT4/B7-H3 co-expression is signiﬁcantly associated
with a reduction in T inﬁltrating lymphoid cells and lower overall survival. In summary, ILT4
increases B7-H3 expression and ILT4/B7-H3 co-expression may be involved in NSCLC progression.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Lung cancer is the leading cause of cancer-related deaths world-
wide [1]. Non-small cell lung cancer (NSCLC) accounts for 80–85%
of all lung cancers [2]. Despite notable efforts to develop novel
therapeutic strategies, overall 5-year survival among NSCLC
patients is approximately 17%. This survival rate is signiﬁcantly
lower than those of the vast majority of malignant carcinomas,
due in part to diagnosis at an advanced stage of metastasis [3,4].
Therefore, a better understanding of the molecular mechanisms
that contribute to NSCLC progression and metastasis is critical for
conquering this disease.
Immunoglobulin-like transcript (ILT) 4 belongs to the family of
immunoglobulin-like transcripts and is mainly expressed in mono-
cytes, dendritic cells (DCs) and endothelial cells [5]. ILT4 induces a
tolerogenic phenotype of human DCs, consequently inductingimmunosuppressive T cells and inhibiting T cell activation and pro-
liferation [6,7]. ILT4 is over-expressed in leukaemia, breast cancer
and NSCLC cells [8–11]. In mouse acute myeloid leukaemia
(AML) transplantation models, the ILT4 mouse orthologue, paired
immunoglobulin-like receptor (PIRB), supports AML development
by inhibiting the differentiation of leukaemia cells [11]. We have
previously demonstrated that ILT4 is signiﬁcantly correlated with
a reduction in T inﬁltrating lymphoid cells (TILs) in breast cancer
and NSCLC and with IL-10 levels in breast cancer [9,10], suggesting
an inhibitory function of ILT4 in tumour immunity. However, the
molecular mechanisms underlying the involvement of ILT4 in the
tumour immune response remain poorly understood.
Inhibitory members of the B7 family are over-expressed in mul-
tiple cancers and contribute to tumour immune evasion by inhibit-
ing T cell activation [12–14]. Among them, B7-H3 is an adverse
prognostic biomarker and has been implicated in NSCLC progres-
sion by inhibiting T cell function and inducing the transformation
of monocytes into tumour-associated macrophages [15–18].
Tumour immune evasion plays an important role in promoting
tumour progression andmetastasis, and this tumourigenic function
may require interactions among tumour-derived immune mole-
cules [19]. Considering the similar functions of ILT4 and B7-H3 in
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connection between ILT4 and B7-H3 in tumour progression.
There is no evidence of a cause-effect relationship between ILT4
and B7-H3 in NSCLC. In the present study, B7-H3 expression was
analyzed upon over-expression or silencing of ILT4 in vitro, and
the potential signalling affecting ILT4-induced B7-H3 expression
was investigated. Furthermore, the co-expression of ILT4 and
B7-H3 was evaluated in human NSCLC tissues, and the relationship
with clinicopathological features and survival was analyzed. OurFig. 1. Effect of ILT4 on the regulation of B7-H3 expression in NSCLC cells. (A) Gene expres
Red: high expression; green: low expression. (B)–(E) ILT4 was over-expressed using ILT4
cells was assayed at both the mRNA and protein levels. NC vector was used as a negative
A549 and H226 cells, and the expression of B7-H3 was assayed at both the mRNA and pro
of three independent experiments. The error bars indicate ±S.E.M. of three independentresults provide a new perspective on the underlying mechanism
of NSCLC progression.
2. Materials and methods
2.1. Cell culture
NSCLC cell lines H1650, H226, H1299, H1975 and A549 (Type
Culture Collection of the Chinese Academy of Sciences, Beijing,sion levels of the B7 family in H1650 cells transfected with ILT4 or control plasmids.
expression plasmids (ILT4 vector), and the expression of B7-H3 in H1650 and H1299
control. (F)–(I) ILT4 was knocked down using ILT4 shRNA (shILT4-1 and shILT4-2) in
tein levels. NC shRNA was used as a negative control. These data are representative
experiments. *P < 0.05; **P < 0.01 by Student’s t-test.
2250 P. Zhang et al. / FEBS Letters 589 (2015) 2248–2256China) were obtained and cultured in RPMI-1640 Medium (Gibco,
Carlsbad, CA, USA) supplemented with 10% FBS (Gibco).
2.2. Patients and samples
A total of 118 primary NSCLC specimens obtained by surgical
resection were collected from Jinan Central Hospital Afﬁliated to
Shandong University, China from 2008 to 2013. This study was
approved by the review board and ethics committee, and all
patients provided written informed consent. Patients (90 men
and 28 women with a mean age at diagnosis of 61 years old) with-
out any preoperative therapy were included in the study. Patients
from whom samples were collected from 2008 to 2010 were con-
tacted by phone to conﬁrm their health status. The last censor date
was September 30, 2014.
2.3. Reverse transcriptase-polymerase chain reaction (RT-PCR)
analysis
Total RNA was isolated using the RNA isolation reagent TRIzol
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
instruction. cDNA was synthesized from total RNA using a reverse
transcription kit (Fermentas, Ontario, Canada). Real-time PCR wasFig. 2. ILT4 activates the PI3K/AKT/mTOR signalling pathway. Increased protein levels of p
E) and H1299 cells (B and F) compared with negative control cells. Decreased protein lev
(C and G) and H226 (D and H) cells compared with negative control cells. These data are
three independent experiments. *P < 0.05; **P < 0.01 by Student’s t-test.performed using the ABI7500 sequence detector (Applied Bio sys-
tems, Foster City, CA, USA) and ILT4 primers (forward, 50-GCATCT
TGGATTACACGGATACG-30; reverse, 50-CTGACAGCCATATCGCCCT
G-30), B7-H3 primers (forward, 50-GGCAGCCTATGACATTCCCC-30;
reverse, 50-GTCTTGGAGCCTTCTCCCTC-30), and GAPDH primers
(forward, 50-AGAAGGCTGGGGCTCATTTG-30, reverse, 50-AGGGGCC
ATCCACAGTCTTC-30). ILT4 and B7-H3 mRNA expression were nor-
malized to GAPDH expression. Gene expression for real-time PCR
was calculated as the change relative to the control (2DDCt).
2.4. Western blot analysis
Total protein was separated and then transferred onto polyvi-
nylidene diﬂuoride membranes (Millipore, Boston, MA, USA). The
membranes were incubated with the following primary antibo-
dies: anti-ILT4 mAb (1:400; Abgent, San Diego, CA, USA),
anti-B7-H3 pAb (1:500; Epitomics, Burlingame, CA, USA),
anti-phospho-ERK pAb (1:1000; Epitomics), anti-ERK pAb
(1:1000; Cell Signalling Technology, Danvers, MA, USA),
anti-phospho-AKT pAb (1:1000; Epitomics), anti-AKT pAb
(1:1000; Epitomics), anti-phospho-mTOR pAb (1:1000; Cell
Signalling Technology), anti-mTOR pAb (1:1000; Cell Signalling
Technology) and anti-GAPDH pAb (1:10000; Proteintech Group,ERK, pAKT and pmTOR were observed when ILT4 was up-regulated in H1650 (A and
els of pERK, pAKT and pmTOR were observed when ILT4 was knocked down in A549
representative of three independent experiments. The error bars indicate ±S.E.M. of
P. Zhang et al. / FEBS Letters 589 (2015) 2248–2256 2251Inc., Wuhan, China). Blots were developed in ECL reagent
(Beyotime Institute Biotechnology, Nantong, China) and imaged
using a ChemiDoc™ XRS+ system (Bio-RAD, Hercules, CA, USA).
2.5. Cell transfection
An expression plasmid containing ILT4, Pez-lv105-ILT4 (ILT4),
and a negative control plasmid, Pez-lv105 (NC) (GeneCopoeia,
Rockville, MD, USA), were transfected into H1650 and H1299 cells.
Knockdown of ILT4 expression was achieved by transfecting
pGPU6/GFP/Neo-shILT4-1 (shILT4-1) or pGPU6/GFP/Neo-shILT4-2
(shILT4-2) (Genechem Co. Shanghai, China) into A549 and H226
cells. A plasmid containing a non-targeting hairpin (shNC) was
used as the negative control. The following shRNA sequences were
used: shILT4-1, 50-GAAGAAGAACACCCACAATGC-30; shILT4-2, 50-G
CTATGGTTATGACTTGAACT-30; and shNC, 50-GTTCTCCGAACGTGTC
ACGT-30. A total of 2  105 cells were transfected with 2 lg of plas-
mid using X-treme GENE HP Reagent (Roche, Basel, Switzerland) in
6-well plates. The cells were collected for RT-PCR andWestern blot
36 h and 48 h after transfection, respectively. The transfection efﬁ-
ciency was determined by detecting ILT4 expression using RT-PCR
and Western blot.
2.6. Signal transduction inhibitor treatment
Cells were incubated in 6-well plates for 24 h after transfection
and then cultured with medium containing the ERK inhibitor
U0126 (Selleck, Houston, TX, USA), the AKT inhibitor LY294002
(Selleck) or the mTOR inhibitor rapamycin (Alexis, Lausen,
Switzerland) for 24 h. Cellular proteins were extracted and sub-
jected to Western blot analysis.
2.7. Gene expression proﬁling
RNA from the NSCLC cell line H1650 transfected with ILT4 and
control plasmids was harvested using TRIzol reagent 40 h after
transfection. Microarray analysis was performed to visualize differ-
ences in gene expression between the H1650 cells transfected with
ILT4 or the control plasmid. The mRNA was ampliﬁed and labelledFig. 3. PI3K/AKT/mTOR signalling inﬂuences B7-H3 expression in NSCLC cell lines. (A) an
AKT inhibitor LY294002 compared with DMSO-treated cells. (C) and (D) Protein expre
rapamycin compared with DMSO-treated cells. (E) and (F) Protein expression of B7-H3 in
DMSO-treated cells. These data are representative of three independent experiments. The
Student’s t-test.using an Agilent Quick Amp labelling kit (Agilent Technologies,
Palo Alto, CA, USA), and the probes were hybridized using a
Whole Human Genome Oligo Microarray (Agilent Technologies).
The processed slides were scanned with an Agilent DNA microar-
ray scanner, and the data were collected and analyzed using the
Agilent Feature Extraction software (version 11.0.1.1) and the
GeneSpring GX software (version 11.5.1).
2.8. Immunohistochemistry analysis
Sections with a thickness of 4 lm were prepared for immuno-
histological staining. The sections were antigen retrieved using
citric acid buffer with heating in a microwave oven for 10 min.
The sections were then incubated overnight at 4 C with anti-ILT4
mAb (1:400; Abgent), anti-B7-H3 pAb (1:200; Epitomics),
anti-pAKT pAb (1:150; Epitomics) or anti-CD45RO mAb (1:100;
Abcam, Cambridge, MA, USA). The sections were incubated with
Enhanced primer and HRP goat anti-mouse/rabbit IgG polymer
using the Elivision™ plus Polymer HRP (Mouse/Rabbit) IHC Kit
(MXB) and visualized with 3,30-diaminobenzidine solution (MXB).
Immunohistochemical assays were analyzed simultaneously by
two independent investigators. The sections were scored as
positive when the tumour cells exhibited positive staining in the
membrane, cytoplasm, and/or nucleus. The proportion score repre-
sented the estimated fraction of positive tumour cells (0 = none;
1 = less than 25%; 2 = 25–75%; 3 = greater than 75%). The intensity
score represented the estimated average staining intensity of posi-
tive tumour cells (0 = none; 1 = weak; 2 = intermediate, 3 = strong).
The overall amount of protein present was then expressed as the
total score of tumour cell (ranges = 0–9, respectively). Positive
scores were deﬁned as P4, and negative scores were deﬁned as
<4. To evaluate the inﬁltration of TILs, we counted the number of
CD45RO+ cells per 1000 total nuclei as described previously [20].
2.9. Statistical analysis
SPSS version 19.0 (SPSS, Chicago, IL, USA) was used for statisti-
cal analysis. Data were represented as means ± S.E.M. (standard
error of the mean). The associations between the expression ofd (B) Protein expression of B7-H3 in A549 and H226 cells after treatment with the
ssion of B7-H3 in A549 and H226 cells after treatment with the mTOR inhibitor
A549 and H226 cells after treatment with the ERK inhibitor U0126 compared with
error bars indicate ±S.E.M. of three independent experiments. *P < 0.05; **P < 0.01 by
Fig. 4. ILT4 over-expression up-regulates B7-H3 expression via PI3K/AKT/mTOR signalling in NSCLC cells. Protein expression of B7-H3 in ILT4 over-expressing H1650 (A and
B) and H1299 cells (G and H) after treatment with the AKT inhibitor LY294002 compared with control cells. Protein expression of B7-H3 in ILT4 over-expressing H1650 (C and
D) and H1299 cells (I and J) after treatment with the mTOR inhibitor rapamycin compared with control cells. Protein expression of B7-H3 in ILT4 over-expressing H1650 (E
and F) and H1299 (K and L) cells after treatment with the ERK inhibitor U0126, compared with control cells. These data are representative of three independent experiments.
The error bars indicate ±S.E.M. of three independent experiments. *P < 0.05; **P < 0.01 by Student’s t-test.
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analyzed using the v2 test and the two-tailed Student’s t test.
Survival curves were drawn using the Kaplan–Meier method and
compared using the log-rank test. P values were considered to indi-
cate signiﬁcant differences at P < 0.05.
3. Results
3.1. ILT4 increases B7-H3 expression in NSCLC cells
To clarify the function and mechanism of tumour-associated
ILT4, we performed gene expression proﬁling and identiﬁed sev-
eral molecules related to the immune response that were altered
in response to ILT4 over-expression. Most of the inhibitory mem-
bers of the B7 family, including B7-H3, were deregulated in ILT4
over-expressing NSCLC cells (Fig. 1A and Supplementary Fig. 1).Thus, we hypothesized that there may be a signiﬁcant causal rela-
tionship between ILT4 and B7-H3.
To conﬁrm this result, we over-expressed ILT4 in H1650 and
H1299 cells and knocked down ILT4 in A549 and H226 cells.
B7-H3 expression was signiﬁcantly increased in ILT4
over-expressing H1650 and H1299 cells (Fig. 1B–E and
Supplementary Fig. 2) and down-regulated when ILT4 expression
was silenced in A549 and H226 cells (Fig. 1F–I).
3.2. ILT4 signiﬁcantly promoted the phosphorylation of signaling
transduction molecules AKT and mTOR
Hyper-activation of PI3K/AKT/mTOR and ERK signalling are the
main drivers of tumour progression in the majority of NSCLC. Thus,
we evaluated whether ILT4 can activate these signalling cascades.
We previously demonstrated that ILT4 can activate ERK signalling.
Fig. 5. Co-expression of ILT4 and B7-H3 in primary human NSCLC tissues. (A) Positive co-expression of ILT4, p-AKT and B7-H3 in tumour cells of representative NSCLC
specimens (magniﬁcation, 200). (B) ILT4 expression was detected in B7-H3-positive specimens compared with B7-H3-negative specimens. (C) ILT4 expression was detected
in pAKT-positive specimens compared with pAKT-negative specimens.
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response to ILT4 over-expression in H1650 and H1299 cells
(Fig. 2A, B, E and F) and un-phosphorylated in response to ILT4
knockdown in A549 and H226 cells (Fig. 2C, D, G and H), suggesting
that ILT4 can activate not only ERK signalling but also
PI3K/AKT/mTOR signalling.
3.3. Effects of PI3K/AKT/mTOR signaling on B7-H3 expression in NSCLC
cells
To investigate the potential effects of PI3K/AKT/mTOR and ERK
signalling on B7-H3 expression, A549 and H226 cells with endo-
genous high B7-H3 expression were treated with inhibitors of
AKT (LY294002), mTOR (rapamycin) and ERK (U0126). Compared
with the control group, treatment with LY294002 or rapamycin
led to a signiﬁcant decrease in B7-H3 expression in A549 and
H226 cells (Fig. 3A–D). However, treatment with U0126 could
not signiﬁcantly inﬂuence B7-H3 expression (Fig. 3E and F).
3.4. ILT4 increases B7-H3 expression through PI3K/AKT/mTOR
signalling
Next, we assessed the signalling cascade linking ILT4 to B7-H3
up-regulation using inhibitors. Compared with the control, treat-
ment with LY294002 or rapamycin led to a signiﬁcant decrease
in B7-H3 expression in ILT4 over-expressing H1650 and H1299cells (Fig. 4A–D and G–J). However, treatment with U0126 did
not signiﬁcantly inﬂuence B7-H3 expression (Fig. 4E, F, K and L).
3.5. Co-expression of ILT4 and B7-H3 in primary human NSCLC tissues
A total of 118 primary humanNSCLC specimens were collected to
examine ILT4 andB7-H3 expression by immunohistochemical analy-
sis. ILT4 expression was detected in the nucleus, cytoplasm and
membrane of cancer cells (Fig. 5A). B7-H3 expression was detected
in the cell cytoplasm or/and membrane (Fig. 5A). ILT4 and B7-H3
expression were occasionally observed in stromal cells. ILT4 and
B7-H3 expression was observed in 46.6% (55/118) and 60.2%
(71/118) of the tissue samples, respectively. There was a signiﬁcant
positive correlation between ILT4 and B7-H3 expression; higher
levels of ILT4 were observed in B7-H3-positive tissues compared
with the corresponding B7-H3-negative tissues (P = 0.021) (Fig. 5B).
Patients were classiﬁed into 4 groups according to ILT4 and
B7-H3 expression. As shown in Table 1, 31.4% patients (37/118)
exhibited positive expression of both ILT4 and B7-H3 (I+B+),
15.3% (18/118) exhibited positive expression of ILT4 but negative
expression of B7-H3 (I+B), 26.2% (31/118) exhibited positive
expression of B7-H3 but negative expression of ILT4 (IB+), and
27.1% (32/118) exhibited negative expression of both ILT4 and
B7-H3 (IB). The I+B+ group was signiﬁcantly associated with
increased regional lymph node involvement (P = 0.001) and
advanced stage (P = 0.001) compared with the IB group. Also,
Table 1
Correlations of ILT4/B7-H3 co-expression with clinicopathological parameters in primary NSCLC tissues.
Variables ILT4+/B7-H3+ ILT4+/B7-H3- ILT4-/B7-H3+ ILT4-/B7-H3-
n n p 1 n p 2 n p 3
Age (yr)
<60 12 5 0.259 16 0.586 16 0.138
P60 15 13 15 16
Gender
Male 27 17 0.131 25 0.458 21 0.508
Female 10 1 6 11
Smoking history (yr)
<30 10 1 0.131 6 0.458 15 0.087
P30 27 17 25 17
Histology
Non-squamous NSCLC 17 10 0.504 17 0.465 22 0.057
Squamous NSCLC 20 8 14 10
Cellular differentiation
Well 14 6 0.745 16 0.255 22 0.01
Worse 23 12 15 10
Primary tumor size (cm)
<5 24 13 0.585 17 0.4 17 0.322
P5 13 5 14 15
Regional lymph node involvement
N0–N1 20 14 0.16 28 0.003 31 0.001
N2–N3 17 4 3 1
2009 TNM stage groupings
I–II 15 13 0.027 24 0.002 28 0.001
III 22 5 7 4
Note: p 1, P value between ILT4+/B7-H3+ and ILT4+/B7-H3-; p 2, P value between ILT4+/B7-H3+ and ILT4-/B7-H3+; p 3, P value between ILT4+/B7-H3+ and ILT4-/B7-H3-.
Abbreviations: NSCLC, non-small cell lung cancer; TNM, tumor node metastasis.
Fig. 6. The relationship between ILT4/B7-H3 co-expression and the number of TILs
in primary human NSCLC tissues. Comparison of TIL intensity between patients
with negative vs. positive ILT4 (A) or B7-H3 (B) expression. (C) Comparison of TIL
intensity in I+/B+, I+B, IB+ and IB tissues. I+/B+: positive expression of both
ILT4 and B7-H3; IB: negative expression of both ILT4 and B7-H3; IB+: positive
expression of B7-H3 but negative expression of ILT4; I+B: positive expression of
ILT4 but negative expression of B7-H3. The error bars indicate ±S.E.M. *P < 0.05;
**P < 0.01 by Student’s t-test.
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regional lymph node involvement (P = 0.003) and advanced stage
(P = 0.002) compared with the IB+ group, and advanced stage
(P = 0.027) when compared with the I+B group.
In addition, we detected expression of pAKT in primary human
NSCLC tissues. pAKT expression was observed in the cytoplasm of
primary NSCLC cells in 57.6% (60/118) of the tissue samples
(Fig. 5A). ILT4 levels were also higher in pAKT-positive samples
compared with pAKT-negative tissues (P = 0.163); however, this
correlation was not signiﬁcant (Fig. 5C).
3.6. Correlation between ILT4/B7-H3 co-expression and the number of
TILs
As previously reported, ILT4 and B7-H3 were correlated with
fewer TILs. The mean number of TILs was 32.35 ± 13.69 in the
ILT4-positive group and 38.20 ± 13.76 in the ILT4-negative group
(P = 0.026; Fig. 6A). In addition, the mean number of TILs was
32.34 ± 13.33 in the B7-H3-positive group, which was signiﬁcantly
lower than that in the B7-H3-negative group (39.15 ± 13.17,
P = 0.002; Fig. 6B).
Furthermore, the relationship between ILT4/B7-H3
co-expression and TILs was examined in clinical specimens. The
mean number of TILs was 30.09 ± 13.99 in the I+B+ group, which
was much lower than that in the IB group (40.87 ± 14.38,
P = 0.007). The number of TILs was also smaller in the I+B+ group
compared to the I+B group (37.22 ± 11.87, P = 0.055) or the
IB+ group (36.51 ± 13.31, P = 0.104), but the difference was not
signiﬁcant (Fig. 6C).
3.7. Relationship between ILT4/B7-H3 co-expression and overall
survival of patients
Importantly, we examined the signiﬁcance of ILT4/B7-H3
co-expression for prognosis in NSCLC patients. Kaplan–Meier
Fig. 7. Relationship between ILT4/B7-H3 co-expression and patient survival. (A) Survival analysis of I+/B+ and I/B NSCLC patients was performed by Kaplan–Meier survival
analysis. (B) Survival analysis of I+/B+ and I/B+ NSCLC patients. (C) Survival analysis of I+/B+ and I+/B NSCLC patients. (D) Survival analysis of I+/A+ and I/A NSCLC
patients. I+A+: positive expression of both ILT4 and pAKT; IA: negative expression of both ILT4 and pAKT.
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I+B+ status was much lower than that of patients with I/B status
(Fig. 7A, P = 0.029). However, no signiﬁcant difference in OS was
observed between I+B+ and IB+ or I+B patients (Fig. 7B and C,
IB+, P = 0.532; I+B, P = 0.202).
In addition, the OS of patients with ILT4/pAKT co-expression
was also lower than patients in the other three groups, but this
difference was not signiﬁcant (Fig. 7D, IA, P = 0.176;
Supplementary Fig. 3, IA+, P = 0.121; I+A, P = 0.179).
4. Discussion
ILT4 expression is up-regulated in NSCLC cells and is associated
with a lower number of TILs [10]. Prior to this study, ILT4 had been
established as a primary molecule responsible for inhibiting
immune function in the immune response [6,7,21]; however, the
role of ILT4 expression in NSCLC progression remains unexplored.
Here, we demonstrated that B7-H3 is up-regulated in ILT4
over-expressing NSCLC cells and that there is a signiﬁcant correla-
tion between ILT4 and B7-H3 expression in primary NSCLC tissues.
B7-H3, an inhibitor of the B7 family, is expressed in various cancers
including breast cancer, colorectal cancer and NSCLC [22,23].
Although conﬂicting effects of B7-H3 have been observed in some
tumours, B7-H3 is considered an inhibitory molecule and repre-
sents a promising target for immune-based antitumour therapies
[24–27]. We ﬁrst established that B7-H3 is expressed in NSCLC
cells and correlates with a reduction in the number of TILs in
tumour tissues [28]. Other groups have demonstrated that B7-H3
expression clearly inhibits T cell-mediated antitumour immunity
in NSCLC [15,16]. Interestingly, we also previously demonstrated
that ILT4 expression in NSCLC cells is negatively correlated with
the number of TILs, indicating a potential role of ILT4 in the
inhibition of T cell function in the tumour environment similar to
that of B7-H3 [10]. In this study, we observed that ILT4/B7-H3
co-expression in patients was associated with a much lowernumber of TILs as well as other adverse clinicopathological
features, including lymph node metastases and advanced tumour
stage compared with other patient groups. Importantly,
ILT4/B7-H3 co-expression was correlated with poor overall survi-
val. Given the signiﬁcant function of TILs in NSCLC progression
[29,30], we conclude that ILT4 may inhibit the T cell-mediated
antitumour immune response by up-regulating B7-H3 expression
in NSCLC tissues, leading to NSCLC progression. Additionally, ILT4
and B7-H3 may synergistically act as biomarkers of negative clin-
ical outcome in NSCLC patients.
As one of the most important signalling pathways in NSCLC, the
PI3K/AKT/mTOR pathway participates in nearly all inspects of
NSCLC development by regulating the expression of various
cancer-related genes [31–33]. Recent studies have demonstrated
that PI3K/AKT/mTOR signalling inﬂuences B7-H1 expression in
melanoma and glioma cells [34–36]. Our results indicated that
ILT4 activated the PI3K/AKT/mTOR signalling pathway, and block-
ing this pathway led to a down-regulation in B7-H3 expression.
However, we did not detect a correlation between ILT4 and pAKT
in NSCLC tissues. Additionally, ILT4/pAKT co-expression was not
correlated with overall survival, which may be due to complex fac-
tors in human NSCLC tissues and an insufﬁcient number of samples.
Collectively, ILT4 may exert its inhibitory function on the
immune response toward the tumour by up-regulating B7-H3 via
PI3K/AKT/mTOR signalling. Moreover, based on the non-
immunological functions of PI3K/AKT/mTOR signalling and B7-H3
[37–41], ILT4 may also have a non-immunological role in tumour
progression. Further studies are needed to gain a better under-
standing of the role of ILT4 in individual features of NSCLC.
In summary, our results demonstrate that ILT4 up-regulates
B7-H3 expression via PI3K/AKT/mTOR signalling. Activation of
the ILT4-PI3K/AKT/mTOR-B7-H3 axis may be involved in tumour
immune evasion, leading to NSCLC progression. These data suggest
a critical role of ILT4 in NSCLC progression and pave the way for
novel antitumour treatment.
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